Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals partners with Bayer, securing up to $2.35 M in milestone‑based funding and exclusivity to develop U.S. iodine contrast media, aiming to cut supply‑chain dependence and boost medical imaging supplies.

Voyageur Pharmaceuticals’ stock hits a new low after a volatile 2025; negative P/E and high P/B signal investor caution and the need for strategic change.

Voyageur Pharmaceuticals’ volatile TSX stock reflects its lithium & barium sulfate focus—investors eye future growth amid current financial challenges.